Uppsala, Sweden, February 16, 2017. The American Association for Cancer Research (AACR) Annual Meeting on April 1-5 will gather the world’s leading cancer researchers and oncologists. Together with its research partners Dana Farber Cancer Institute and the Karolinska Institute, Biovica will present new data on the company’s DiviTum™ assay as a response marker for CDK4/6 inhibition.
“At AACR, we will present new study results that enhance the rationale and evidence for DiviTum™ as an efficacy marker of CDK4/6 inhibition. CDK4/6 inhibitors are important additions to the treatment of metastatic breast cancer and DiviTum is the first blood-based biomarker for evaluating their efficacy. With DiviTum™, we want to contribute to better patient outcome and improve cost efficacy of these new drugs, says Anders Rylander, CEO Biovica.”